Associate Editor, Ophthalmology Times
NHL ophthalmologist on eye injuries and eye health in professional sports
July 1st 2024Ashley Brissette, MD, MSc, FRCSC, team ophthalmologist for the New York Rangers sat down to talk about eye injuries in hockey and other professional sports, as well as advancements in prevention and treatment for the players.
Read More
AMA adopts new policy to ensure diversity in clinical trials and research
June 14th 2024Under the new policy, grant-making entities will be encouraged to fund post-market research investigating pharmacodynamics and pharmacokinetics for generic drugs that did not adequately enroll women, and sexual and gender minority populations in their clinical trials.
Read More
IOP outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with DME
June 3rd 2024Mark Barakat, MD, sat down with Ophthalmology Times to discuss intraocular pressure outcomes with intravitreal injection of aflibercept, 8mg and 2mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial.
Read More
A post hoc analysis of the phase 2/3 PHOTON trial
June 2nd 2024Sean Adrean, MD, FAAO, sat down with Ophthalmology Times to discuss a post hoc analysis of the phase 2/3 PHOTON trial and the outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg.
Read More
Impact of baseline CRT on vision among patients with DME
June 1st 2024Deepak Sambhara, MD, sat down with Ophthalmology Times to discuss the impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME), as a post hoc analysis of the phase 2/3 PHOTON trial.
Read More
IKA 2024: Likelihood of progression in keratoconus patients
May 20th 2024William Trattler, MD, talked about his session at the IKA 2024 Symposium that discussed the progression of keratoconus in patients and just how likely it is for them to progress and the importance of following up with these patients.
Read More